An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS)
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- NCT01674907
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational study will evaluate the use in clinical practice and the efficacy of Avastin (bevacizumab) in patients with metastatic colorectal cancer who have not received prior chemotherapy treatment in the metastatic setting. Patients for whom the treating physician has decided to initiate therapy with Avastin will be followed for 10 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
- Adult patients, >/= 18 years of age
- Histologically confirmed metastatic colorectal cancer without prior chemotherapy in the metastatic setting
Exclusion Criteria
- Contraindications for Avastin according to the locally approved package insert (version 7 April 2006)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical/demographic patient characteristics at baseline approximately 3 years Dosage/schedule of 1st-line Avastin approximately 3 years Chemotherapy regimens used in clinical practice approximately 3 years Duration of treatment approximately 3 years
- Secondary Outcome Measures
Name Time Method Relationship between termination of Avastin treatment and time point of progression approximately 3 years Progression-free survival approximately 3 years